Firstly, they have a complementary diagnostic value, since some anti-ACPA-negative sera tested positive with the new chimeric peptides, suggesting they may help identify additional RA cases that would be missed by existing tests. This evidence concerns the gene PRTN3 and rheumatoid arthritis.